Tom Harrity
Bristol-Myers Squibb (United States)(US)
Publications by Year
Research Areas
Microbial Natural Products and Biosynthesis, Diabetes Treatment and Management, Carbohydrate Chemistry and Synthesis, Peptidase Inhibition and Analysis, Alkaloids: synthesis and pharmacology
Most-Cited Works
- → Optimization of Activity, Selectivity, and Liability Profiles in 5-Oxopyrrolopyridine DPP4 Inhibitors Leading to Clinical Candidate (Sa)-2-(3-(Aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778)(2013)44 cited
- → 7-Oxopyrrolopyridine-derived DPP4 inhibitors—mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site(2011)18 cited